Literature DB >> 25028482

Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics.

Hugo Poulin1, Iva Bruhova1, Quadiri Timour1, Olivier Theriault1, Jean-Martin Beaulieu1, Dominique Frassati1, Mohamed Chahine2.   

Abstract

The voltage-gated Nav1.5 channel is essential for the propagation of action potentials in the heart. Malfunctions of this channel are known to cause hereditary diseases. It is a prime target for class 1 antiarrhythmic drugs and a number of antidepressants. Our study investigated the Nav1.5 blocking properties of fluoxetine, a selective serotonin reuptake inhibitor. Nav1.5 channels were expressed in HEK-293 cells, and Na(+) currents were recorded using the patch-clamp technique. Dose-response curves of racemic fluoxetine (IC50 = 39 μM) and its optical isomers had a similar IC50 [40 and 47 μM for the (+) and (-) isomers, respectively]. Norfluoxetine, a fluoxetine metabolite, had a higher affinity than fluoxetine, with an IC50 of 29 μM. Fluoxetine inhibited currents in a frequency-dependent manner, shifted steady-state inactivation to more hyperpolarized potentials, and slowed the recovery of Nav1.5 from inactivation. Mutating a phenylalanine (F1760) and a tyrosine (Y1767) in the S6 segment of domain (D) IV (DIVS6) significantly reduced the affinity of fluoxetine and its frequency-dependent inhibition. We used a noninactivating Nav1.5 mutant to show that fluoxetine displays open-channel block behavior. The molecular model of fluoxetine in Nav1.5 was in agreement with mutational experiments in which F1760 and Y1767 were found to be the key residues in binding fluoxetine. We concluded that fluoxetine blocks Nav1.5 by binding to the class 1 antiarrhythmic site. The blocking of cardiac Na(+) channels should be taken into consideration when prescribing fluoxetine alone or in association with other drugs that may be cardiotoxic or for patients with conduction disorders.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25028482      PMCID: PMC4164981          DOI: 10.1124/mol.114.093104

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  42 in total

1.  Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.

Authors:  Hai Huang; Silvia G Priori; Carlo Napolitano; Michael E O'Leary; Mohamed Chahine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

Review 2.  Clinical aspects and physiopathology of Brugada syndrome: review of current concepts.

Authors:  E Herbert; M Chahine
Journal:  Can J Physiol Pharmacol       Date:  2006 Aug-Sep       Impact factor: 2.273

Review 3.  Tricyclic antidepressant poisoning : cardiovascular toxicity.

Authors:  H K Ruben Thanacoody; Simon H L Thomas
Journal:  Toxicol Rev       Date:  2005

4.  On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex.

Authors:  A R Harmer; J-P Valentin; C E Pollard
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

6.  Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices.

Authors:  E C Hennings; J P Kiss; K De Oliveira; P T Toth; E S Vizi
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

7.  Lidocaine block of human heart sodium channels expressed in Xenopus oocytes.

Authors:  M Chahine; L Q Chen; R L Barchi; R G Kallen; R Horn
Journal:  J Mol Cell Cardiol       Date:  1992-11       Impact factor: 5.000

8.  Differential effects of fluoxetine enantiomers in mammalian neural and cardiac tissues.

Authors:  János Magyar; Zoltán Rusznák; Csaba Harasztosi; Agnes Körtvély; Pál Pacher; Tamás Bányász; Csaba Pankucsi; László Kovács; Géza Szûcs; Péter P Nánási; Valéria Kecskeméti
Journal:  Int J Mol Med       Date:  2003-04       Impact factor: 4.101

9.  Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor.

Authors:  B Eisensamer; G Rammes; G Gimpl; M Shapa; U Ferrari; G Hapfelmeier; B Bondy; C Parsons; K Gilling; W Zieglgänsberger; F Holsboer; R Rupprecht
Journal:  Mol Psychiatry       Date:  2003-11       Impact factor: 15.992

10.  Role of the C-terminal domain in the structure and function of tetrameric sodium channels.

Authors:  Claire Bagnéris; Paul G Decaen; Benjamin A Hall; Claire E Naylor; David E Clapham; Christopher W M Kay; B A Wallace
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  11 in total

1.  Modeling the human Nav1.5 sodium channel: structural and mechanistic insights of ion permeation and drug blockade.

Authors:  Marawan Ahmed; Horia Jalily Hasani; Aravindhan Ganesan; Michael Houghton; Khaled Barakat
Journal:  Drug Des Devel Ther       Date:  2017-08-04       Impact factor: 4.162

2.  Inhibitory effects of neferine on Nav1.5 channels expressed in HEK293 cells.

Authors:  Chen Wang; Huan Wang; Jun-Hua Xiao; Jia-Ling Wang; Ji-Zhou Xiang; Qiang Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

Review 3.  Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.

Authors:  Tomas Koltai
Journal:  F1000Res       Date:  2015-07-22

4.  hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.

Authors:  André Monteiro da Rocha; Katherine Campbell; Sergey Mironov; Jiang Jiang; Lakshmi Mundada; Guadalupe Guerrero-Serna; José Jalife; Todd J Herron
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

5.  Carcinoid heart disease involving the left heart: a case report and biomarker analysis.

Authors:  Michael Lichtenauer; Tristan Pichler; Sarah Eder; Moritz Mirna; Theresa Magnes; Bernhard Wernly; Vera Paar; Christian Jung; Erika Prinz; Rainald Seitelberger; Uta C Hoppe
Journal:  ESC Heart Fail       Date:  2019-01-08

6.  Fluoxetine Suppresses Glutamate- and GABA-Mediated Neurotransmission by Altering SNARE Complex.

Authors:  Vesna Lazarevic; Ioannis Mantas; Ivana Flais; Per Svenningsson
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

Review 7.  Pathogenesis and management of Brugada syndrome in schizophrenia: A scoping review.

Authors:  Anuj Rastogi; Dylan Viani-Walsh; Shareef Akbari; Nicholas Gall; Fiona Gaughran; John Lally
Journal:  Gen Hosp Psychiatry       Date:  2020-10-06       Impact factor: 3.238

Review 8.  Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.

Authors:  Steven C Mitini-Nkhoma; Elizabeth T Chimbayo; David T Mzinza; David V Mhango; Aaron P Chirambo; Christine Mandalasi; Agness E Lakudzala; Dumizulu L Tembo; Kondwani C Jambo; Henry C Mwandumba
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

9.  MTSET modification of D4S6 cysteines stabilize the fast inactivated state of Nav1.5 sodium channels.

Authors:  Michael E O'Leary; Mohamed Chahine
Journal:  Front Pharmacol       Date:  2015-06-19       Impact factor: 5.810

10.  Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores.

Authors:  Rafik Tadros; Hanno L Tan; Sulayman El Mathari; Jan A Kors; Pieter G Postema; Najim Lahrouchi; Leander Beekman; Milena Radivojkov-Blagojevic; Ahmad S Amin; Thomas Meitinger; Michael W Tanck; Arthur A Wilde; Connie R Bezzina
Journal:  Eur Heart J       Date:  2019-10-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.